Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5
NCT03520712 · BioMarin Pharmaceutical · PHASE1/PHASE2 · terminated · last registry update 2025-08-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Early rollover into long-term extension study” | – | Registry record, BioMarin Pharmaceutical |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-14Results posted on the registry: Pfizer, PF-06741086 (NCT03938792)
- 2026-07-31Results posted on the registry: Spur Therapeutics, verbrinacogene setparvovec (NCT05164471)
- 2026-07-31Also stopped (terminated): Spur Therapeutics, verbrinacogene setparvovec (NCT05164471)
- 2026-07-24Also stopped (terminated): AstraZeneca, Ceralasertib + Drug X (NCT06929260)
- 2026-06-25Also stopped (terminated): Octapharma, Octaplex (NCT04867837)
- 2026-06-24Results posted on the registry: SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-06-24Also stopped (terminated): SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-04-07Also stopped (withdrawn): University of Texas Southwestern Medical Center, Eloctate + Adynovate (NCT04690322)
- 2026-02-27Phase 3 first posted: Chulalongkorn University, Switching to low dose emicizumab (NCT07439055)
- 2026-02-18Phase 3 first posted: Hoffmann-La Roche, NXT007 + Emicizumab (NCT07416604)
- 2025-12-10Also stopped (terminated): CSL Behring, BE1116 + Placebo (NCT05568888)
- 2025-11-10Results posted on the registry: CSL Behring, BE1116 + Placebo (NCT05568888)
- 2025-11-06Results posted on the registry: Pfizer, Standard of Care FIX Replacement therapy + Standard of Care FVIII Replacement therapy (NCT03587116)
- 2025-08-15Results posted on the registry: Octapharma, Octaplex + Frozen Plasma Product, Human (NCT05523297)
- 2025-07-30Phase 3 first posted: CSL Behring, BE1116 + FFP (NCT07094087)
- 2025-07-23Phase 3 first posted: CSL Behring, CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) (NCT07080905)
- 2025-06-05Results posted on the registry: Takeda, a drug against F9 (NCT05437211)
- 2025-05-31Phase 3 first posted: Hoffmann-La Roche, Emicizumab + von Willebrand Factor (VWF) Concentrates (NCT06998524)
- 2025-05-31Results posted on the registry: Novo Nordisk A/S, Nonacog beta pegol (NCT05365217)
- 2025-04-22Phase 3 first posted: Dhaka Medical College, Emicizumab Injection + Factor VIII (FVIII) (NCT06938659)
- 2025-04-10Results posted on the registry: BioMarin Pharmaceutical, valoctocogene roxaparvovec (NCT02576795)
- 2025-01-16Results posted on the registry: Swedish Orphan Biovitrum, a drug against F9 (NCT05856266)
- 2025-01-16Also stopped (terminated): Swedish Orphan Biovitrum, a drug against F9 (NCT05856266)
- 2024-12-13Also stopped (withdrawn): Spark Therapeutics, Inc., SPK-8011 (NCT06297486)
- 2024-11-26Results posted on the registry: Washington University School of Medicine, Transdermal patch + Daily Sublingual Tablet (NCT05010707)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision